HLA–DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Cohort Study

Arthritis and Rheumatology

Volumn 68, Issue 7, 2016, Pages 1721-1730

  Hilhorst, Marc ^a   Arndt, Fabian ^b   Joseph Kemna, Michael ^a   Wieczorek, Stefan ^c   Donner, Yoni ^d   Wilde, Benjamin ^e   Thomas Epplen, Jörg ^c   van Paassen, Pieter ^a   Cohen Tervaert, Jan Willem ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Klinikum Bad Bramstedt   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; HLA DPB1 ANTIGEN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB;

ADULT; ALLELE; ANCA ASSOCIATED VASCULITIS; ARTICLE; CARDIOVASCULAR RISK; CHROMOSOME 6; COHORT ANALYSIS; CONTROLLED STUDY; EOSINOPHILIC GRANULOMA; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL RATE; VALIDATION STUDY; WEGENER GRANULOMATOSIS;

EID: 84976582516     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39620     Document Type: Article

References (38)

1. De Lind van Wijngaarden R, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody-associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol 2008;3:237–52.
2. Wilde B, van Paassen P, Witzke O, Tervaert JW. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011;79:599–612.
3. Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ, et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int 2000;57:2195–206.
4. Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema M, van der Hem G. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990;37:799–806.
5. Hilhorst M, van Paassen P, Tervaert JW. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol 2015;10:2314–27.
6. Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis 2013;72:1273–9.
7. Monach P, Merkel PA. Genetics of vasculitis. Curr Opin Rheumatol 2010;22:157–63.
8. Jagiello P, Gencik M, Arning L, Wieczorek S, Kunstmann E, Csernok E, et al. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 2004;114:468–77.
9. Arning L, Holle J, Harper L, Millar D, Gross WL, Epplen J, et al. Are there specific genetic risk factors for the different forms of ANCA-associated vasculitis? Ann Rheum Dis 2008;70:707–8.
10. Lyons P, Rayner T, Trivedi S, Holle J, Watts R, Jayne D, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214–23.
11. Heckmann M, Holle J, Arning L, Knaup S, Hellmich B, Nothnagel M, et al. The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. Ann Rheum Dis 2008;67:972–9.
12. Xie G, Roshandel D, Sherva R, Monach P, Lu E, Kung T, et al. Association of granulomatosis with polyangiitis (Wegener's) with HLA–DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum 2013;65:2457–68.
13. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.
14. Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert J. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005;46:253–62.
15. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222–7.
16. Abdulkader R, Lane S, Scott D, Watts R. Classification of vasculitis: EMA classification using CHCC 2012 definitions. Ann Rheum Dis 2013;72:1888.
17. Hellmich B, Flossmann O, Gross WL, Bacon PA, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605–17.
18. Levey A, Gassman J, Hall P, Walker W. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. J Am Soc Nephrol 1991;1:1087–94.
19. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827–32.
20. Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda Vriesman P, Cohen Tervaert JW. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 2013;28:373–9.
21. Jones R, Tervaert JW, Hauser T, Luqmani RA, Morgan M, Peh C, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–20.
22. Berden A, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628–36.
23. Hviid T, Madsen H, Morling N. HLA-DPB1 typing with polymerase chain reactions and restriction fragment length polymorphism technique in Danes. Tissue Antigens 1992;40:140–4.
24. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365–86.
25. Mukhtyar C, Flossmann O, Hellmich B, Bacon PA, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004–10.
26. Tripepi G, Jager K, Stel V, Dekker F, Zoccali C. How to deal with continuous and dichotomic outcomes in epidemiological research: linear and logistic regression analyses. Nephron Clin Pract 2011;118:c399–406.
27. Latouche A, Porcher R, Chevret S. Sample size formula for proportional hazards modelling of competing risks. Stat Med 2004;23:3263–74.
28. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
29. Papiha S, Murty G, Ad'Hia A, Mains B, Venning M. Association of Wegener's granulomatosis with HLA antigens and other genetic markers. Ann Rheum Dis 1992;51:246–8.
30. Stassen P, Cohen-Tervaert JW, Lems S, Hepkema B, Kallenberg C, Stegeman CA. HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. Rheumatology 2009;48:622–5.
31. Hagen EC, Stegeman CA, D'Amaro J, Schreuder G, Lems S, Tervaert JW, et al. Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis. Kidney Int 1995;48:801–5.
32. Cao Y, Schmitz J, Yang J, Hogan S, Bunch D, Hu Y, et al. DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 2011;22:1161–7.
33. Chang D, Luo H, Zhou X, Chen M, Zhao M. Association of HLA genes with clinical outcomes of ANCA-associated vasculitis. Clin J Am Soc Nephrol 2012;7:1293–9.
34. Slot M, Cohen Tervaert JW, Boomsma M, Stegeman C. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3–related vasculitis. Arthritis Rheum 2004;51:269–73.
35. Wieczorek S, Hellmich B, Gross WL, Epplen J. Associations of Churg-Strauss syndrome with the HLA–DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody–associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum 2008;58:329–30.
36. Concannon P, Rich S, Nepom G. Genetics of type 1A diabetes. N Engl J Med 2009;360:1646–54.
37. Farrell R, Kelly C. Celiac sprue. N Engl J Med 2002;346:180–8.
38. Tervaert J, van der Woude F, Fauci A, Ambrus J, Velosa J, Keane W, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149:2461–5.